The Safety and Efficacy of Intra-Arterial versus Intravenous Neoadjuvant Chemotherapy in Patients with Locally Advanced Cervical Cancer: A Meta-Analysis

Table 1

Study design of eligible studies.

Study	Study type	Stage	Age (average)	NACT regimen	Duration of NACT	Safety assessment
Saito et al. [11]	Prospective cohort study	IB-IIIB	28–75 (45.4)	CDDP 70 mg/m2; ACM 30 mg/m2; MMC 5 mg/m2	Every 14 days for two cycles	HT and NHT
Shibata et al. [12]	Prospective cohort study	IB2-IIIB	29–73 (46.5)	5-FU 700 mg/m2; 5-FU 700 mg/m2	Every 22 days for two cycles	HT and NHT
Wen et al. [10]	RCT	IB2-IIA	17–75 (44.8)	CDDP 50 mg/m2; 5-FU 700 mg/m2	Every 14 days for two cycles	HT and NHT

RCT, randomized controlled trial; CDDP, cisplatin; ACM, aciacinomycin; MMC, mitomycin; 5-FU, 5-fluorouracil; HT, hematological toxicities; NHT, nonhematological toxicities.